RYZNEUTA

Growth

efbemalenograstim alfa-vuxw

BLAINJECTIONINJECTABLE

Approved

Nov 2023

Lifecycle

Growth

Competitive Pressure

30/100

Mechanism of Action

Pharmacologic Class:

Leukocyte Growth Factor

Company

China - Shanghai

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers